Research

IN THIS SECTION 1. Overview 2. Research Focus 3. Projects 4. Publications

 

Publications

 

2004 - 2005

2005

Borer JS. Aortic stenosis and statins: more evidence of “pleotropy”? Arteriosclerosis Thrombosis and Vascular Biology 2005;25:476-477. 

Supino PG, Borer JS, Prebisz J, Herrold EM, Hochreiter CA, Kligfield P, Roman MJ. Prognostic impact of systolic hypertension on asymptomatic patients with chronic severe aortic regurgitation and initially normal left ventricular performance at rest. American Journal of Cardiology 2005;96:964-970.

Vassiliades TA, Block PC, Cohn LH, Adams DH, Borer JS, Feldman T, Holmes DR, Laskey WK, Lytle BW, Mack MJ, Williams DO. The clinical development of percutaneous heart valve technology: a position statement of the Society of Thoracic Surgeons (STS), the American Association for Thoracic Surgery (AATS), and the Society of Cardiovascular Angiography and Interventions. Journal of Thoracic and Cardiovascular Surgery 2005;129:970-976; Annals of Thoracic Surgery 2005;79:1812-1818; Journal of the American College of Cardiology 2005;45:1554-1560.

Germano G, Berman D, Borer JS. Myocardial function assessment by nuclear techniques in Atlas of Nuclear Cardiology, Edition 2 (eds: Dilsizian V, Narula J, Braunwald E), Current Medicine, Inc. (Philadelphia), 2005, pp. 115-142.

Borer JS. Heart rate slowing with the If  inhibitor, ivabradine, for angina prevention: results of clinical trials. European Heart Journal Supplements 2005; 7 (supplement H): H22-H28.

Borer JS, Simon L. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and non-selective NSAIDs: achieving a balance. Arthritis Research and Therapy 2005;7(Suppl 4):S14-22.

Borer JS. Receiving the torch. Cardiology, 2005;104:I-II.

Borer JS. If inhibition as a therapeutic approach to stable angina: evidence from experimental and clinical studies. Medicographia 2005;27:44-50

2004

Supino PG, Herrold EM, Braegelmann F, Borer JS. Left ventricular ejection fraction change with exercise  vs ejection fraction at rest in coronary artery disease: implications for using ejection fraction variations in making therapeutic decisions. American Journal of Therapeutics 2004;11:164-170.

Borer JS. Left ventricular hypertrophy in hypertrophic cardiomyopathy: what’s in a phenotype? Journal of the American College of Cardiology 2004;44:406-408.

Mann DL, McMurray J, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anti-cytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation 2004;109:1594-1602..

Borer JS, Truter SL, Gupta A, Herrold EM, Carter JN, Lee E, Pitlor L.    Heart failure in aortic regurgitation: the role of primary fibrosis and its cellular and molecular pathophysiology. Advances in Cardiology 2004; 41:16-24.

Hochreiter C, Borer JS, Yin A, Supino P, Herrold EM, Krieger K, Isom OW. Ventricular arrhythmias in mitral regurgitation: frequency, clinical and prognostic importance, management before and after mitral valve surgery. Advances in Cardiology 2004; 41:108-111.

Borer JS, Supino P, Hochreiter C, Herrold EM, Yin A, Krieger K, Isom OW. Valve surgery in the asymptomatic patient with aortic regurgitation: current indications and the effect of change rates in objective measures.  Advances in Cardiology 2004; 41:36-47.

Supino PG, Borer JS. Yin A, Dillingham E, McClymont W. The epidemiology of valvular heart diseases: the problem is growing. Advances in Cardiology 2004; 41: 9-15.

Borer JS, Kupfer K. Mitral regurgitation: current treatment options and their selection. Current Treatment Options in Cardiovascular Medicine 2004;6:509-517.

Borer JS.  Development of cardiovascular drugs: the U.S. regulatory milieu from the perspective of a participating nonregulator. Journal of the American College of Cardiology, 2004;44:2285-2292.

Truter SL, Dumlao TF, Lee JA, Lee E, Supino PG, Borer JS. Vesnarinone-mediated alterations of gene expression in cardiac fibroblasts from aortic regurgitant hearts. American Journal of Therapeutics 2004;11:328-336.

Borer JS. Heart rate reduction: a therapeutic target in cardiovascular disease. Advances in Heart Rate Reduction 2004;1:1-3.

Borer JS. If inhibitors as specific heart rate reducing agents. Nature (Clinical Practice Cardiovascular) 2004,1:1-7.

 

 

< Prev

Next >